Last reviewed 2026-04-20 · How we verify

PD0332991 (pd0332991)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Neutropenia
• Fatigue
• Leukopenia
• Thrombocytopenia
• Anemia
• Arthralgia
• Nausea
• Hot flush
• Infection
• Anaemia
• Neutrophil count decreased
• Stomatitis

Key clinical trials

• Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) (PHASE2)
• Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (PHASE1)
• Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) (PHASE2)
• A Study of the Use of Text Message Reminders to Take Palbociclib (NA)
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (PHASE2)
• Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PD0332991 CI brief — competitive landscape report
• PD0332991 updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI